# First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients With Pancreatic Cancer

> **NCT05141149** · PHASE1,PHASE2 · RECRUITING · sponsor: **Prestige Biopharma Limited** · enrollment: 80 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** PBP1510 (400mg/16mL)
- **DRUG:** Gemcitabine (1000 mg/m^2)

## Key facts

- **NCT ID:** NCT05141149
- **Lead sponsor:** Prestige Biopharma Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-05
- **Primary completion:** 2026-02
- **Final completion:** 2026-12
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05141149

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05141149, "First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients With Pancreatic Cancer". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT05141149. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*